BBK Worldwide has utilized a secure data “tunnel” that allows biopharmaceutical companies to leverage the power of the Apple® iPad® 2 cost-efficiently. BBK is introducing the e-BinderSM 2–an Apple iPad 2 specifically customized for the research and development community and its regulatory guidelines–at the Drug Information Association’s Annual Meeting commencing this week in Chicago.
One of the major barriers to implementing a franchise or multi-study communications program using the iPad 2–despite its convenience and effectiveness–is the risk of unpredictable monthly data costs associated with the use of a 3G network. BBK’s e-Binder 2 completely mitigates this risk. The e-Binder 2 deploys a proprietary virtual “tunnel” that permits only designated IP addresses to be accessible through a 3G network, with other sites available using aWi-Fi connection. “By identifying this global tunnel, BBK has enabled clients to deploy the e-Binder as a work tool and be confident that data consumption is for study-related activities,” said BBK Worldwide CEO Joan F. Bachenheimer.
Today, many study protocols undergo more than five amendments. As each country’s regulatory bodies approve these amendments, the content accessible through the e-Binder 2 can be updated electronically within minutes.
Earlier this month, BBK deployed 50 e-Binders to clinical research associates working throughout Eastern Europe and Latin America to drive enrollment for a multinational multiple sclerosis study.
BBK partners with sister company TCN e-Systems to deploy patient recruitment solutions via mobile and online technologies. Direct connections between the e-Binder and the sponsor’s web-based portals, as well as content updates, are managed by TCN e-Systems.
BBK will exhibit the e-Binder 2 and other technology solutions for patient recruitment at the 47th annual meeting of the Drug Information Association, 19 – 23 June 2011, in Chicago (booth # 1616).